Advertisement

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Amit Sanyal, MD: A Clinician’s Perspective

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Welcome and Introduction to Vi3C

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Advertisement

Advertisement




Jul
01
Today In Oncology
Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma
FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer
ASCO Remembers Karnofsky Award Recipient Maura Gillison Pioneer in HPV-Associated Cancers
Novel Risk Score Stratifies Major Bleeding Risks in Patients With VTE on DOACs
Long-Term Outcomes With SABR in Primary Kidney Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo